CYPRUS ORGANIZATION FOR THE PROMOTION OF QUALITY
CYPRUS ACCREDITATION BODY

ACCREDITATION CERTIFICATE no. L088-2

The Board of Governors
of the Cyprus Organization for the Promotion of Quality,
the National Accreditation Body,
in accordance with the Article 7 of the Law 156(I)/2002

GRANTS ACCREDITATION to

LABORATORIES of
THE KARAISKAKIO FOUNDATION

in Nicosia

The Departments/Laboratories shown in annexes were assessed according to the Accreditation Criteria for Medical Laboratories, as defined in the Standard

CYS EN ISO 15189:2012

and were found technically competent to carry out the **Tests** included in the Scope of Accreditation which is described in the **Annexes** to this Certificate and is an **integrated part of it. The Scope of Accreditation** can change only after approval from the Cyprus Accreditation Body.

The current Accreditation Certificate, no. **L088-2**, **is issued on the 3rd September 2021 and is valid from 20th September 2020 until the 19th September 2024.**

Accreditation was awarded for the first time on the 20th September 2016.

Antonis Ioannou
Director

Date: **3rd September 2021**

This laboratory is accredited in accordance with the recognised International Standard ISO 15189:2012. This accreditation demonstrates technical competence for a defined scope and the operation of a laboratory quality management System (ISO-ILAC-IAF Communiqué, January 2015).

Annex

to the Accreditation Certificate no. L088-2 (CG)

SCOPE OF ACCREDITATION

for

THE KARAISKAKIO FOUNDATION LABORATORIES CYTOGENOMICS (CG)

Materials/ Products	Types of Tests	Methods applied/ Technical fields
Peripheral Blood, Bone Marrow	Interphace Fluorescence in situ hybridization ("FISH")	Interphase FISH using enumeration, break apart and fusion probes (CE-IVD). Hybridization Detection and Analysis using ThermoBrite Hybridization Machine and GenASIs Scan and Analysis System.
Peripheral Blood, Bone Marrow or Tissue	Analysis for copy number changes	CGH array protocol by Agilent. DNA labeling, hybridization, scanning, interpretation. MS 200 NimbleGen Scanner Agilent Cytogenomics Software

Authorised persons to sign the test reports are Dr Paul Costeas or Dr Jason Chi.

SCOPE OF ACCREDITATION

for

THE KARAISKAKIO FOUNDATION LABORATORIES MOLECULAR HAEMATOLOGY-ONCOLOGY (MH)

*Valid as from the 1st April 2021 till the 19th September 2024.

Materials /Products	Types of examinations	Methods applied / Technical fields
Peripheral Blood, Bone Marrow or Tissue	"Sample Processing" by isolation of PBMCs, nucleic acid extraction and storage of stabilized cells for future testing	In House Protocol: FBC (Sysmex), Erythrocyte lysis, RNA extraction (QIAGEN QIAcube), DNA extraction (QIAGEN QIAcubeor RBC MagCore), RNAlater (QIAGEN)
Peripheral Blood, Bone Marrow	"Multiplex Fusion Gene Screening" for the detection of the following 28 distinct fusion transcripts associated with different type of haematological malignancies: del1(p32) (STIL-TAL1), t(1;11) (p32;q23) (MLL-EPS15), (1;11) (q21;q23) (MLL-MLLT11), t(1;19) (q23;p13) (TCF3-PBX1), t(3;5) (q25;q34) (NPM1-MLF1), t(3;21) (q26;q22) (RUNX1-MECOM), t(4;11) (q21;q23) (MLL-AFF1), t(5;12) (q33;p13) (ETV6-PDGFRB), t(5;17) (q35;q21) (NPM1-RARA), t(6;9) (p23;q34) (DEK-NUP214), t(6;11) (q27;q23) (MLL-MLLT4), t(8;21) (q22;q22) (RUNX1-RUNX1T1), t(9;9) (q34;q34) (SET-NUP214), t(9;11) (p22;q23) (MLL-MLLT3), t(9;12) (q34;p13) (ETV6-ABL1), t(9,22) (q34;q11) (BCR-ABL1), t(10;11) (p12;q23) (MLL-MLLT10), t(11;17) (q23;q21) (MLL-MLLT6), t(11;17) (q23;q21) (ZBTB16-RARA), t(11;19) (q23;p13.1) (MLL-ELL), t(11;19) (q23;p13.3) (MLL-MLLT1), t(12;21) (p13;q22) (ETV6-RUNX1), t(12;22) (p13;q11) (ETV6-MN1), t(15;17) (q24;q21) (PML-RARA), inv(16) (p13;q22) (CBFB-MYH11), t(16;21) (p11;q22) (FUS-ERG), t(17;19) (q22;p13) (TCF3-HLF), t(X;11) (q13;q23) (MLL-FOXO4)	Hemavision Screen (CE-IVD): Tandem nested multiplex RT-PCR and electrophoresis

Peripheral Blood, Bone Marrow	"Fusion Transcript QNT" of fusion gene transcripts: ratio to control gene transcript (t(1;19)(q23;p13) E2A-PBX1, t(4;11)(q21;q23) MLL-AF4, t(12;21)(p13;q22) TEL-AML1, t(9;22)(q34;q11) BCR-ABL m-bcr, t(9;22)(q34;q11) BCR-ABL M-bcr, del(1)(p32p32) SIL-TAL1, t(15;17)(q22;q21) PML-RARA, inv(16)(p13q22) CBFB-MYH11, t(8;21)(q22;q22) AML1-ETO)	EAC Protocol: RT-qPCR, BioRad CFX96 Real Time System
Peripheral Blood, Bone Marrow or Tissue	Mutation detection (JAK2 p.V617F, c-KIT p.D816V, BRAF p.V600E, MYD88 p.L265P)	In House Protocol: Single tube semi-nested PCR, Allele Specific Oligonucleotide (ASO) priming, gel electrophoresis
Peripheral Blood, Bone Marrow	Mutation Screening (JAK2 exon 12, BCR-ABL kinase domain, TP53, Hemoglobin Alpha, Beta and Delta gene)	In House Protocol: PCR amplification, Sanger DNA Sequencing 3500XL Sequencer
Peripheral Blood	Mutation Detection 1) CVD: FV G1691A (Leiden), FV H1299R (R2), Prothrombin G20210A, Factor XIII V34L, β-Fibrinogen -455 G-A, PAI-1 4G/5G, GPIIIa L33P (HPA-1), MTHFR C677T, MTHFR A1298C, ACE I/D, Apo B R3500Q, Apo E2/E3/E4 2) TPMT alleles #1, #2, #3A, #3B, #3C 3) Alpha-globin gene mutations: 3.7 single gene deletion, 4.2 single gene deletion, MED double gene deletion, SEA double gene deletion, THAI double gene deletion, FIL double gene deletion, 20.5 kb double gene deletion, anti-3.7 gene triplication, a1 cd 14 [TGG>TAG], a1 cd 59 [GGC>GAC] (Hb Adana), a2 init cd [ATG>ACG], a2 cd 19 [-G], a2 IVS1 [-5nt], a2 cd 59 [GGC>GAC], a2 cd 125 [CTG>CCG] (Hb Quong Sze), a2 cd 142 [TAA>CAA] (Hb Constant Spring), a2 cd 142 [TAA>AAA] (Hb Icaria), a2 cd 142 [TAA>TAT] (Hb Pakse), a2 cd 142 [TAA>TCA] (Hb Koya Dora), a2 poly A-1 [AATAAA-AATAAG], a2 poly A-2 [AATAAA-AATGAA]. 4) Beta-globin gene mutations: - 101 [C>T], - 87 [C>G], - 30 [T>A], codon 5 [-CT], codon 6 [G>A] HbC, codon 6 [A>T] HbS, codon 6 [-A], codon 8 [-AA], codon 8/9 [+G], codon 15 [TGG>TGA], codon 27 [G>T] Knossos, IVS 1.1 [G>A], IVS 1.5 [G>C], IVS 1.6 [T>C], IVS 1.110 [G>A], IVS 1.116 [T>G], IVS 1.130 [G>C], codon 39 [C>T], codon 44 [-C], IVS 2.1 [G>A], IVS 2.745 [C>G], IVS 2.848 [C>A] 5) CYP2C9 #2, #3	ViennaLab StripAssay SSO (CE-IVD) PCR array hybridization Auto-Lipa (hybridization)

Peripheral Blood, Bone Marrow	Chimerism detection of donor DNA component percentage in post-transplant sample	GenDX KMRtype & KMRtrack Chimerism Monitoring (CE-IVD) ABI 7500 Real Time PCR System KMRengine Analysis Software
Peripheral Blood, Bone Marrow or Tissue	Germline Mutation Detection by whole exome and targeted exome sequencing	Agilent SureSelect Enrichment Protocol (Library Preparation) Illumina (NGS Sequencing) Saphetor Clinical Varsome Software Analysis
Peripheral Blood, Bone Marrow	IGH and TCR sequencing by NGS, IGHV somatic mutation analysis	Invivoscribe LymphoTrack Dx (CE-IVD) Illumina NGS Sequencing LymphoTrack Analysis Software
Peripheral Blood, Bone Marrow	MRD Detection in Lymphoid Malignancies using Patient Specific Immunoglobulin or T-Cell Receptor Allele Specific Oligonucleotide (ASO)-based Real-Time PCR	In house ASO Primer Design, Real Time PCR BioRad CFX96 Real Time System
Peripheral Blood, Bone Marrow or Tissue	FusionPlex Screening for fusions, splicing or exon skipping in the following genes: **Sarcoma:** ALK, EPC, GLI1, MKL2, PLAG1, TAF15, USP6, CAMTA1, EWSR1, HMGA2, NCOA2, ROS1, TCF12, YWHAE, CCNB3, FKHR, JAZF1, NTRK3, SS18, TFE3, CIC, FUS, MEAF6, PDGFB, STAT6, TFG. **Thyroid and Lung Cancer:** AKT1, ALK, AXL, BRAF, CALCA, CCND1, CTNNB1, DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, GNAS, HRAS, IDH1, IDH2, KRAS, KRT20, KRT7, MAP2K1, MET, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PIK3CA, PPARG, PTH, RAF1, RET, ROS1, SLC5A5, THADA, TTF1 **Solid Tumors:** AKT3, EWSR1, NOTCH1/2, RAF1, ALK, FGFR1/2/3, NRG1, RELA, ARHGAP26, FGR, NTRK1/2/3, RET, AXL, INSR, NUMBL, ROS1, BRAF, MAML2, NUTM1, RSPO2/3, BRD3/4, MAST1/2, PDGFRA/B, TERT, EGFR, MET, PIK3CA, TFE3, ERG, MSMB, PKN1, TFEB, ESR1, MUSK, PPARG, THADA, ETV1/4/5/6, MYB, PRKCA/B, TMPRSS2	Archer FusionPlex assay (Library Preparation) Illumina NGS Sequencing Archer Bioinformatics Analysis Software

	Myeloid Malignancies: ABL1, AKT3, ASXL1, BCR, BRAF, CALR, CBFB, CBL, CD274, CEBPA, CHD1, CHIC2, CREBBP, CSF1R, CSF3R, CTLA4, DCK, DNM2, DNMT3A, ERG, ETV6, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GATA1, GATA2, GLIS2, GNAS, ID4, IDH1, IDH2, IKZF1, IKZF3, IRF4, IRF8, JAK1, JAK2, JAK3, KAT6A, KDM6A, KIT, KMT2A, KRAS, MECOM, , MKL1, MLLT10, MLLT4, MPL, MUC1, MYC, MYD88, MYH11, NF1, NOTCH1, NPM1, NRAS, NUP214, NUP98, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PHF6, PICALM, PML, PTPN11, RARARBM15, ROS1, RUNX1, RUNX1T1, SETBP1, SETD2, SF3B1, SLC29A1, SRSF2, TCF3, TFG, U2AF1, WT1XPO1 **Acute Lymphoblastic Leukaemia:** ABL1, ABL2, AICDA, BCL11B, BCL, BCL6, BCR, BLNK, BRAF, CD274, CHD1, CREBBP, CRLF2, CSF1R, CTLA4, DNM2, DNTT, EBF1, EPOR, ETV6, EZH2, FBXW7, FGFR1, FLT3, HOXA10, HOXA9, IDH1, IDH2, IKZF1, IKZF2, IKZF3, IL7R, IRF4, IRF8, JAK1, JAK2, JAK3, KDM6A, KLF2, KMT2A, KRAS, LMO1, LYL1, MLLT4, MPL, MYC, NF1, NOTCH1, NRAS, NT5C2, NTRK3, NUP214, NUP98, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PTK2B, PTPN11, RAG1, RAG2, RUNX1, SEMA6A, SETD2, SH2B3, SOX11, STAT3, STAT5B, STIL, TAL1, TCF3, TLX1, TLX3, TYK2, WT1, ZCCHC7 **Lymphoma:** AICDA AKT3 ALK ASB13 BATF3 BAX BCL2 BCL2A1 BCL3 BCL6 BCR BIRC3 BLNK BMF BMP7 BRAF BTK CARD11 CBFB CCDC50 CCND1 CCND2 CCND3 CD274 CD44 CD79B CDC25A CDK6 CDKN2A CDKN2B CEBPD CEBPE CEBPG CHIC2 CIITA CREB3L2 CREBBP CTLA4 CYB5R2 DEK DENND3 DLEU1 DNMT3A DNMT3B DNTT DUSP22 E2F2 EIF4A1 ENTPD1 ETV6 EXOC2 EZH2 FAM216A FBXW7 FGFR1 FOXP1 FUT8 IDH1 IDH2 IL16 IRF4 IRF8 ITPKB JAK1 JAK2 JAK3 KIAA0101 KMT2A KRAS LIMD1 LMO2 LRMP LZTS1 MAL MALT1 MAML3 MKL1 MLF1 MLLT10 MME MUC1 MYBL1 MYC MYD88 NEK6 NFKB1 NFKB2 NME1 NOTCH1 NOTCH2 NRAS P2RY8 PAICS PDCD1 PDCD1LG2 PDGFRA PIM1 PIM2 PLCG1 PLCG2 PPAT PRDM16 PRKAR2B PTPN1 PYCR1 RAB29 RAG1 RAG2 RANBP1 RHOA S1PR2 SERPINA9 SF3B1 SH3BP5 STAT3 STAT5B STAT6 STIL STRBP TCF3 TNFRSF13B TNFSF4 TP63 WT1 XPO1	

	Hematological Malignancies: ABL1, ABL2, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, CBFB, CCND1, CCND2, CCND3, CD274, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FOXP1, GLIS2, ID4, IKZF1, IKZF2, IKZF3, IRF4, IRF8, JAK2, KAT6A, KLF2, KMT2A, MALT1, MECOM, MKL1, MLF1, MLLT10, MLLT4, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, P2RY8, PAG1, PAX5, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, TAL1, TCF3, TFG, TP63, TYK2, ZCCHC7	
Peripheral Blood, Bone Marrow or Tissue	VariantPlex Screening for single nucleotide variants (SNVs), copy number, variations (CNVs), insertions and deletions in the following genes: **Thyroid and Lung Cancer:** AKT1, ALK, BRAF, CCND1, CTNNB1, DDR2, EGFR, EIF1AX, ERBB2, FGFR1, FGFR2, FGFR3, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MDM2, MET, NRAS, PDGFRA, PIK3CA, PTEN, RET, ROS1, STK11, TERT, TP53, TSHR **Solid Tumors:** ABL1, AKT1, ALK, APC, ATM, AURKA, BRAF, CCND1, CCNE1, CDH1, CDK4, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, H3F3A, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MDM2, MET, MLH1, MPL, MYC, MYCN, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTEN, PTPN11, RB1, RET, RHOA, ROS1, SMAD4, SMARCB1, SMO, SRC, STK11, TERT, TP53, VHL **Myeloid Malignancies:** ABL1, ANKRD26, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 **Circulating cell-free tumor DNA (ccfDNA / cfDNA / ctDNA):** AKT1, ALK, AR, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ESR1, FGFR1, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, RET, ROS1, SMAD4, TP53	Archer VariantPlex assay, ctDNA assay (Library Preparation) Illumina NGS Sequencing Archer Bioinformatics Analysis Software

Peripheral Blood, Bone Marrow	Indel Detection for FLT3 (ITD), CALR exon9	In House Protocol: PCR amplification, Agarose gel electrophoresis, Fragment Separation and Analysis 3500XL Sequencer
Peripheral Blood, Bone Marrow or Tissue	T Cell Receptor and Immunoglobulin Gene Rearrangement Assays to identifying clonal B-cell and T-cell populations	Invivoscribe Technologies' IdentiClone™ assays (CE-IVD), PCR Amplification, Fragment Separation and Analysis 3500XL Sequencer
Peripheral Blood, Bone Marrow or Tissue	Multiplex ligation-dependent probe amplification (MLPA) MLPA Probe Mixes: P212-DBA, P031-FANCA mix 1, P032-FANCA mix 2, P113-FANCB, P088-Oligodendroglioma 1p-19q, P105-Glioma-2, P472-SUFU, P002-BRCA1, P045-BRCA2/CHEK2, P260-PALB2-RAD50-RAD51C-RAD51D, P190-CHEK2, P043-APC, P251-NB mix 1, P252-NB mix 2, P253-NB mix 3, P067-PTCH1, P225-PTEN, P070-Subtelomeres mix2B, P036-Subtelomeres mix1, P047-RB1, P056-TP53, P016-VHL, P028-FHL, P335-ALL-IKZF1, P037-CLL-1, P038-CLL-2, P081-NF1 mix 1, P082-NF1 mix 2, P044-NF2, P124-TSC1CE, P046-TSC2 Methylation Specific MLPA Probe Mixes: ME012-MGMT-IDH1-IDH2, ME030-BWS/RSS	MRC Holland MLPA and MS-MLPA protocols, Fragment separation (ABI 3500XL sequencer), analysis (Coffalyser Software) MLPA Probe Mixes: P212-DBA, P031-FANCA mix 1, P032-FANCA mix 2, P113-FANCB, P088-Oligodendroglioma 1p-19q, P105-Glioma-2, P472-SUFU, P002-BRCA1, P045-BRCA2/CHEK2 (CE-IVD), P260-PALB2-RAD50-RAD51C-RAD51D (CE-IVD), P190-CHEK2 (CE-IVD), P043-APC (CE-IVD), P251-NB mix 1, P252-NB mix 2, P253-NB mix 3, P067-PTCH1, P225-PTEN (CE-IVD), P070-Subtelomeres mix2B (CE-IVD), P036-Subtelomeres mix1(CE-IVD), P047-RB1 (CE-IVD), P056-TP53(CE-IVD), P016-VHL(CE-IVD), P028-FHL, P335-ALL-IKZF1, P037-CLL-1, P038-CLL-2, P081-NF1 mix 1 (CE-IVD), P082-NF1 mix 2 (CE-IVD), P044-NF2, P124-TSC1CE (CE-IVD),

		P046-TSC2 Methylation Specific MLPA Probe Mixes: ME012-MGMT-IDH1-IDH2, ME030-BWS/RSS
Tissue or Liquid Biopsy	EGFR, KRAS, NRAS, BRAF Mutation detection	Idylla Biocardis BRAF (CE-IVD), KRAS (CE-IVD), NRAS-BRAF (CE-IVD), EGFR (CE-IVD), ctKRAS (CE-IVD), ctNRAS-BRAF (CE-IVD), NRAS-BRAF-EGFR S492R, ctBRAF, ctKRAS, ctNRAS-BRAF-EGFR S492R, ctEGFR
Tissue (FFPE)	*Detection of Microsatellite Instability (MSI) colorectal cancer or in solid tumors in 7 MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2)	Idylla Biocardis (CE-IVD)

Authorised person to sign the test reports is Dr Paul Costeas.
In his absence, Dr Jason Chi or Dr Laura Koumas are authorized to sign reports.

Annex

to the Accreditation Certificate no. L088-2 (IG)

SCOPE OF ACCREDITATION

for

THE KARAISKAKIO FOUNDATION LABORATORIES IMMUNOGENETICS (IG)

Materials /Products	Types of examinations	Methods applied / Technical fields
Peripheral Blood, Bone Marrow	Class I and Class II HLA Genotyping	1) PCR / SSP gel electrophoresis (OlerupSSP) (CE-IVD) 2) PCR/Reserve Array Hybridization (CE-IVD) (Histospot, BAG Healthcare) 3) Next generation sequencing (Holotype, Omixon)

Authorised person to sign the test reports is Dr Paul Costeas.
In his absence, Dr. Laura Koumas is authorized to sign reports.

Annex

to the Accreditation Certificate no. L088-2 (FC)

SCOPE OF ACCREDITATION

for

THE KARAISKAKIO FOUNDATION LABORATORIES
FLOW CYTOMETRY (FC)

Materials /Products	Types of examinations	Methods applied / Technical fields
Peripheral Blood, Bone Marrow, CSF	(1) General Bone Marrow Investigation (2) Basic acute leukemia immunophenotyping (3) Basic LPD immunophenotype (4) B-Acute lymphoblastic leukemia, Minimal Residual Disease (5) Plasma Cell Multiple Myeloma Minimal Residual Disease	Cytoplasmic and surface cellular marker staining, Flow Cytometry Analysis FACS Verse Flow Cytometer
Peripheral Blood	T Lymphocyte Enumeration	BD Trucount Absolut Counting tubes (CE-IVD), CD3/ CD8/ CD45/ CD4 BD Multitest (CE-IVD) surface cellular marker staining, FACS Verse Flow Cytometry Analysis
Peripheral Blood, Bone Marrow	Lymphocyte subpopulation analysis	FACS Verse Flow Cytometry Analysis CD3/ CD4/ CD8/ CD19/ CD16+56
Peripheral Blood	Paroxysmal Nocturnal Hemoglobinuria (PNH)	In-house method Detection of glycophosphatidylinositol (GPI)-linked antigens on hematopoietic cells using monoclonal antibodies FACS Verse
Peripheral Blood, Bone Marrow, Cord Blood and Apheresis Products	CD34+ stem cell enumeration	BD Stem Cell Enumeration assay (CE-IVD), BD FACS Verse
Peripheral Blood	Full Blood Count of Blood Samples by an automated Haematology Analyser (WBC, RBC, HB, HCT, MCV, PLT, NEUT, LYMPH, MONO, EO and BASO)	Full Blood Count of Blood Samples Using the Haematology Analyser Sysmex XT-1800i (CE-IVD)

Authorised person to sign the test reports are Dr Paul Costeas or Dr Laura Koumas.
In their absence, Dr Chryso Pierides is authorized to sign reports.

General Remarks

These Annexes refer **only to tests** carried out **in the premises of the Laboratory**, Address: 15, Nicandrou Papamina Avenue, 2032, Nicosia

Antonis Ioannou
Director

Date: **3rd September 2021**